PHARMACOECONOMIC EVALUATION OF SUNITINIB MALATE FOR FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN MEXICOVALUE IN HEALTHIF62009-05-012OAAI
HEALTH WORKERS' WORK ENVIRONMENT SATISFACTION IN ONCOLOGIC SERVICES AT THE SOCIAL SECURITY MEXICAN INSTITUTEVALUE IN HEALTHIF62009-05-010OAAI
COST-EFFECTIVENESS OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA: A MEXICAN PERSPECTIVEVALUE IN HEALTHIF62009-05-011OAAI
A PHARMACOECONOMIC ANALYSIS OF PROPHYLAXIS THERAPIES AND TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) IN MEXICAN PATIENTS WITH CANCERVALUE IN HEALTHIF62009-05-010OAAI
PREGABALIN FOR THE TREATMENT OF GENERALIZED ANXIETY DISORDERS (GAD) - A COST-EFFECTIVENESS CASE STUDY OF MEXICOVALUE IN HEALTHIF62009-05-010OAAI
PHARMACOECONOMIC EVALUATION OF PHARMACOLOGICAL INTERVENTIONS IN GENERALIZED ANXIETY DISORDERS (GAD) IN MEXICOVALUE IN HEALTHIF62009-05-010OAAI
A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumoursBRITISH JOURNAL OF CANCERIF6.82008-05-2715OAAI
Pharmacoeconomic analysis of antifungal agents for the management of non neutropenic patients with invasive candidiasis at the social security Mexican institute (IMSS)VALUE IN HEALTHIF62008-05-010OAAI
Cost-effectiveness analysis of anidulafungin for the management of invasive candidiasis in non-neutropenic patients in MexicoVALUE IN HEALTHIF62008-05-010OAAI
The economic impact of single-dose azithromycin microspheres formulation for the management of acute streptococcal pharyngitis (ASP) in MexicoVALUE IN HEALTHIF62008-05-010OAAI
Cost-effectiveness analysis of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy in MexicoVALUE IN HEALTHIF62008-05-010OAAI
Cost-effectiveness analysis of immunosuppressive treatments for bone marrow transplantation in patients with aplastic anemia in MexicoVALUE IN HEALTHIF62008-05-010OAAI
Cost-effectiveness assessment of antiepileptic drugs as adjuvant treatments for the management of refractory partial seizures in adult Mexican patientsVALUE IN HEALTHIF62008-05-010OAAI
Pharmacoeconomic evaluation of cabergoline for the management of hyperprolactinemia caused by hypophyseal microadenoma in MexicoVALUE IN HEALTHIF62008-05-010OAAI
Cost-effectiveness analysis of dopamine agonists for the treatment of infertility asociated to hyperprolactinemia in MexicoVALUE IN HEALTHIF62008-05-010OAAI
Economic assessment of sildafenil for the management of patients with erectile dysfunction (ED) secondary to diabetes mellitus type 2 (DM2) and hypertension in MexicoVALUE IN HEALTHIF62008-05-010OAAI
Economic evaluation of polyclonal antibodies for the management of high risk patients with acute rejection in renal transplantation at the Social Security Mexican Institute (IMSS)VALUE IN HEALTHIF62008-05-010OAAI
Pharmacoeconomic evaluation for the treatment of Mexican patients with diabetes type 2VALUE IN HEALTHIF62007-05-010OAAI
A cost -: Utility analysis model for the second line treatment of metastatic renal cell carcinoma in MexicoVALUE IN HEALTHIF62007-05-012OAAI
A cost - Effectiveness analysis model for the second line treatment of gastrointestinal stromal tumours (GIST) in MexicoVALUE IN HEALTHIF62007-05-010OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向